MediWound Ltd.

What they do

MediWound develops and commercializes enzymatic drugs that remove non-viable tissue (eschar) from severe burns and chronic wounds. Its lead product, NexoBrid, is approved in the U.S., EU, and other markets for the removal of eschar in deep partial- and full-thickness thermal burns. The company also has EscharEx in clinical development for chronic wounds, such as venous leg ulcers and diabetic foot ulcers. MediWound is incorporated in Israel and listed on the Nasdaq Global Market.

Revenue drivers

• NexoBrid — Revenue comes from sales of NexoBrid, an enzymatic debridement product approved for severe burns. The company commercializes NexoBrid directly in the U.S. and through distributors and partners in Europe and other regions. It is the primary source of product revenue.
• EscharEx — EscharEx is an investigational product for chronic wound debridement. It is not yet approved and generates no product revenue; the company is investing in clinical trials to support potential future commercialization.

Recent performance

As of December 31, 2025, MediWound had 12,835,148 ordinary shares outstanding. The provided filing excerpts do not include specific revenue, net income, or cash flow figures for the fiscal year ended December 31, 2025. Therefore, detailed recent financial performance cannot be summarized from the available source material.

Strategy

MediWound's stated strategy includes commercializing NexoBrid in the U.S. and expanding its presence in European burn centers. The company is also advancing clinical trials for EscharEx in chronic wounds and for additional NexoBrid indications. Management emphasizes building its marketing team to cover European regional burn centers and units. The company continues to invest in research and development for its pipeline.

Risks

• Regulatory and clinical trial risk — Future revenue from EscharEx depends on successful clinical trials and regulatory approvals, which may be delayed or fail.
• Commercialization and market adoption risk — NexoBrid revenue growth depends on physician adoption and reimbursement, which may be slower than expected.
• Competition risk — MediWound faces competition from other burn and wound care treatments, including surgical debridement and other enzymatic agents.
• Reliance on partners and distributors — International sales depend on third-party distributors, and their performance or contractual disputes could harm revenue.

Outlook

Management's stated priorities include expanding NexoBrid commercialization in the U.S. and Europe, advancing EscharEx clinical development, and pursuing additional indications for NexoBrid. The company's forward-looking statements reference ongoing trials and marketing expansion. Specific financial guidance or timelines are not provided in the available excerpts.